Latest news with #Qiagen
Yahoo
21-07-2025
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen's QIAcuityDx digital PCR platform. The collaboration will focus on developing multiplex cancer assays for use in liquid and tissue biopsies. As the authorized manufacturer, Gencurix will create a number of cancer tests while striving to obtain IVD regulatory clearances. Following approval, Qiagen's global commercial infrastructure will be used for marketing the assays. The collaboration makes use of QIAGEN's QIAcuityDx platform, a member of the QIAcuity family of digital PCR technologies, which by the end of 2024 had achieved over 2,700 total placements. Furthermore, Qiagen N.V. (NYSE:QGEN) recently concluded the acquisition of Genoox for $70 million, with possible extra milestone payments, in order to improve its capacity for genetic data analysis. Qiagen's Digital Insights suite now incorporates Genoox's Franklin platform. A global leader in Sample to Insight solutions, Qiagen N.V. (NYSE:QGEN) offers tools for extracting and analyzing proteins, RNA, and DNA from a variety of samples. While we acknowledge the potential of QGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
Qiagen and Incyte have announced a master collaboration agreement to create a diagnostic panel to aid in the treatment of individuals with a group of rare blood cancers known as myeloproliferative neoplasms (MPNs). This partnership focuses on supporting Incyte's investigational therapies, including the monoclonal antibody INCA033989, which targets mutant calreticulin (mutCALR) in conditions such as myelofibrosis (MF) and essential thrombocythemia (ET). According to the agreement, Qiagen will create a multimodal panel leveraging next-generation sequencing (NGS) to detect clinically relevant gene alterations in haematological malignancies. The validation of the panel will be done by the Illumina NextSeq 550Dx platform as part of Qiagen's collaboration with the latter to provide NGS diagnostic platforms for global laboratory testing. Regulatory submissions and market access activities will be supported by Qiagen across the European Union, the US, and the Asia-Pacific regions. According to Qiagen, MPNs account for approximately 40% of haematological malignancies and are marked by the overproduction of various mature blood cells. Incyte research and development head and president Pablo Cagnoni said: 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with Qiagen, which will facilitate CALR testing for patients with MPNs on a global basis. 'The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF.' Incyte's INCA033989 for mutCALR ET or MF aims to eliminate malignant cells while sparing healthy ones. CALR is said to play a crucial role in managing calcium levels within cells and ensuring the production of proteins. Last month, Qiagen entered a commercial collaboration and joint marketing agreement with ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for applications in oncology research. "Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
06-06-2025
- Business
- Yahoo
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 8.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 6.92% due to these changes. Currently, Qiagen has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Qiagen has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Qiagen belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), has gained 12.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Incyte reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +19.5%. EPS of $1.16 for the same period compares with $0.64 a year ago. For the current quarter, Incyte is expected to post earnings of $1.38 per share, indicating a change of +175.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Incyte. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
